Unknown

Dataset Information

0

Early high antibody titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma.


ABSTRACT:

Background

Several randomised clinical trials have studied convalescent plasma for coronavirus disease 2019 (COVID-19) using different protocols, with different severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) neutralising antibody titres, at different time-points and severities of illness.

Methods

In the prospective multicentre DAWn-plasma trial, adult patients hospitalised with COVID-19 were randomised to 4 units of open-label convalescent plasma combined with standard of care (intervention group) or standard of care alone (control group). Plasma from donors with neutralising antibody titres (50% neutralisation titre (NT50)) ≥1/320 was the product of choice for the study.

Results

Between 2 May 2020 and 26 January 2021, 320 patients were randomised to convalescent plasma and 163 patients to the control group according to a 2:1 allocation scheme. A median (interquartile range) volume of 884 (806-906) mL) convalescent plasma was administered and 80.68% of the units came from donors with neutralising antibody titres (NT50) ≥1/320. Median time from onset of symptoms to randomisation was 7 days. The proportion of patients alive and free of mechanical ventilation on day 15 was not different between both groups (convalescent plasma 83.74% (n=267) versus control 84.05% (n=137)) (OR 0.99, 95% CI 0.59-1.66; p=0.9772). The intervention did not change the natural course of antibody titres. The number of serious or severe adverse events was similar in both study arms and transfusion-related side-effects were reported in 19 out of 320 patients in the intervention group (5.94%).

Conclusions

Transfusion of 4 units of convalescent plasma with high neutralising antibody titres early in hospitalised COVID-19 patients did not result in a significant improvement of clinical status or reduced mortality.

SUBMITTER: Devos T 

PROVIDER: S-EPMC8576805 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications


<h4>Background</h4>Several randomised clinical trials have studied convalescent plasma for coronavirus disease 2019 (COVID-19) using different protocols, with different severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) neutralising antibody titres, at different time-points and severities of illness.<h4>Methods</h4>In the prospective multicentre DAWn-plasma trial, adult patients hospitalised with COVID-19 were randomised to 4 units of open-label convalescent plasma combined with standa  ...[more]

Similar Datasets

| S-EPMC11464705 | biostudies-literature
| S-EPMC8121524 | biostudies-literature
| S-EPMC9877863 | biostudies-literature
| S-EPMC7675325 | biostudies-literature
| S-EPMC11919330 | biostudies-literature
| S-EPMC8828369 | biostudies-literature
| S-EPMC10151238 | biostudies-literature
| S-EPMC8385553 | biostudies-literature
2021-12-09 | GSE189610 | GEO
| S-EPMC9115414 | biostudies-literature